BNP Paribas Financial Markets
AVTX icon

BNP Paribas Financial Markets’s Avalo Therapeutics AVTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Sell
134,087
-288,694
-68% -$4.56M ﹤0.01% 2646
2026
Q1 		$6.31M Buy
422,781
+225,034
+114% +$3.52M ﹤0.01% 1847
2025
Q4 		$3.59M Buy
197,747
+197,742
+3,954,840% +$3.34M ﹤0.01% 2255
2025
Q3 		$64 Hold
5
– – ﹤0.01% 5461
2025
Q2 		$25 Buy
5
+1
+25% +$5 ﹤0.01% 5384
2025
Q1 		$32 Hold
4
– – ﹤0.01% 5306
2024
Q4 		$30 Hold
4
– – ﹤0.01% 5337
2024
Q3 		$38 Hold
4
– – ﹤0.01% 4094
2024
Q2 		$50 Hold
4
– – ﹤0.01% 3989
2024
Q1 		$87 Buy
+4
New +$22 ﹤0.01% 3972
2022
Q4 		– Sell
-3
Closed -$2.38K – 4095
2022
Q3 		$2.38K Buy
+3
New +$3.25K ﹤0.01% 4329
2021
Q3 		– Sell
-1
Closed -$9.75K – 4014
2021
Q2 		$9.75K Sell
1
-1
-50% -$8.38K ﹤0.01% 3734
2021
Q1 		$17.4K Hold
2
– – ﹤0.01% 3779
2020
Q4 		$17.9K Sell
2
-1
-33% -$6.95K ﹤0.01% 3863
2020
Q3 		$21.1K Buy
3
+2
+200% +$15K ﹤0.01% 3819
2020
Q2 		$6.79K Sell
1
-1
-50% -$7.26K ﹤0.01% 3880
2020
Q1 		$17K Buy
2
+1
+100% +$10.6K ﹤0.01% 3941
2019
Q4 		$16.2K Buy
+1
New +$10.5K ﹤0.01% 4051
2019
Q3 		– Hold
0
– – – 4313
2019
Q2 		– Hold
0
– – – 4438

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Financial Markets's AVTX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Avalo Therapeutics (AVTX) stake by 68% in Q2 2026, selling an estimated $4.56M and leaving 134,087 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

BNP Paribas Financial Markets first reported a position in AVTX in Q4 2019 and has held it in 18 quarters since. The position peaked at $6.31M in Q1 2026. 118 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • BNP Paribas Financial Markets held 134,087 shares of Avalo Therapeutics worth $2.48M as of Q2 2026.
  • BNP Paribas Financial Markets sold 288,694 Avalo Therapeutics shares in Q2 2026, an estimated $4.56M.
  • Avalo Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2646 holding.
  • BNP Paribas Financial Markets first reported a position in Avalo Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • BNP Paribas Financial Markets's Avalo Therapeutics position peaked at $6.31M in Q1 2026.
  • 118 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.